These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8736460)

  • 1. No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
    Ligtenberg JJ; Leenaers AD; Van Haeften TW; Smit AJ; Sluiter WJ; Reitsma WD
    J Hum Hypertens; 1996 Apr; 10(4):269-76. PubMed ID: 8736460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.
    Ligtenberg JJ; Van Haeften TW; Van Der Kolk LE; Smit AJ; Sluiter WJ; Reitsma WD; Links TP
    Clin Sci (Lond); 1996 Nov; 91(5):583-9. PubMed ID: 8942397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium channel modulation: effect of pinacidil on insulin release in healthy volunteers.
    Links TP; Smit AJ; Reitsma WD
    J Clin Pharmacol; 1995 Mar; 35(3):291-4. PubMed ID: 7608319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phentolamine precludes inhibitory effect of the K+ channel opener pinacidil on insulin release.
    Links TP; Smit AJ; van Haeften TW; Reitsma WD
    Horm Metab Res; 1996 Jan; 28(1):20-2. PubMed ID: 8820989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of the vasodilator pinacidil on insulin secretion in healthy humans.
    Nielsen-Kudsk JE; Mellemkjaer S; Nielsen CB; Siggaard C
    J Clin Pharmacol; 1990 May; 30(5):409-11. PubMed ID: 2189901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pinacidil inhibits insulin release by increasing K+ outflow from pancreatic B-cells.
    Lebrun P; Devreux V; Hermann M; Herchuelz A
    Eur J Pharmacol; 1988 Nov; 156(2):283-6. PubMed ID: 3071468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell secretion and insulin sensitivity in hypertensive and normotensive obese subjects.
    Bonora E; Moghetti P; Zenere M; Tosi F; Travia D; Muggeo M
    Int J Obes; 1990 Sep; 14(9):735-42. PubMed ID: 2228406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium channels in hypokalaemic periodic paralysis: a key to the pathogenesis?
    Links TP; Smit AJ; Oosterhuis HJ; Reitsma WD
    Clin Sci (Lond); 1993 Sep; 85(3):319-25. PubMed ID: 8403805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated basal insulin secretion and normal dynamic insulin sensitivity in borderline hypertension.
    Piccardo MG; Turchetti G; Rosa MS; Pacini G
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):244-9. PubMed ID: 10656171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial protection with pinacidil cardioplegia in the blood-perfused heart.
    Lawton JS; Harrington GC; Allen CT; Hsia PW; Damiano RJ
    Ann Thorac Surg; 1996 Jun; 61(6):1680-8. PubMed ID: 8651767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects.
    Glaser B; Raveh Y; Norynberg C; Berry E; Lavielle R; Nathan C; Cerasi E
    Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contribution to the study of the mechanism of action of potassium channel activators].
    Lebrun P
    Bull Mem Acad R Med Belg; 1993; 148(1-2):108-14. PubMed ID: 8111337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
    Dorella M; Giusto M; Da Tos V; Campagnolo M; Palatini P; Rossi G; Ceolotto G; Felice M; Semplicini A; Del Prato S
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1568-74. PubMed ID: 8636369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of non-esterified fatty acid concentrations by insulin in patients with hypertension.
    Sheu WH; Jeng CY; Shieh SM; Fuh MM
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Dec; 56(6):367-72. PubMed ID: 8851476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets.
    Lebrun P; Devreux V; Hermann M; Herchuelz A
    J Pharmacol Exp Ther; 1989 Sep; 250(3):1011-8. PubMed ID: 2506332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-sensitive K+ channel opener pinacidil augments beta 1-adrenoceptor-induced coronary vasodilation in dogs.
    Katsuda Y; Egashira K; Ueno H; Arai Y; Akatsuka Y; Kuga T; Shimokawa H; Takeshita A
    Am J Physiol; 1996 Jun; 270(6 Pt 2):H2210-5. PubMed ID: 8764276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women.
    Sleddering MA; Snel M; Streefland TC; Pijl H; Jazet IM
    Eur J Endocrinol; 2012 Dec; 167(6):839-45. PubMed ID: 22983924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.